rovisions primarily in 
relation to Proton therapy and other 
accelerators amounting to EUR 4.2 
million following delivery of several 
projects to customers. New 
provisions 
for 
the 
onerous 
maintenance contracts for EUR 1.8 
million. This increase results from the 
reforecast and increased losses on 1 
contract 
that 
became 
onerous 
previously. The main assumptions used 
were a 2% yearly inflation, cost savings 
initiatives and a discount rate of 2% to 
reflect the impact of time.